Clinical trial
A Phase 1b Placebo-controlled, Multi-centre, Randomized, Double-blind Dose Escalation Study to Evaluate the Pharmacokinetics (PK) and Safety of SMT C1100 in Patients With Duchenne Muscular Dystrophy (DMD) Who Follow a Balanced Diet
NCT02383511 is registered in ClinicalTrials.gov with Summit Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1b Placebo-controlled, Multi-centre, Randomized, Double-blind Dose Escalation Study to Evaluate the Pharmacokinetics (PK) and Safety of SMT C1100 in Patients With Duchenne Muscular Dystrophy (DMD) Who Follow a Balanced Diet
- Lead sponsor
- Summit Therapeutics
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- February 28, 2015
- Completion date
- August 31, 2015
- Enrollment
- 12 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.